Achieve Life Sciences is a pharmaceutical firm developing cytisinicline, a naturally derived compound designed to help people quit smoking by lessening withdrawal symptoms through interaction with brain nicotine receptors. The company is advancing this treatment candidate toward market approval in Canada, the United States, and the United Kingdom, supported by partnerships with Sopharma AD and the University of Bristol. Headquartered in Washington state, the company focuses on addressing nicotine dependence.

entry readiness 45 · WEAK SETUP · exit proximity 0

Value area 5.31–7.64 · 59% of 120d volume overhead · heavy supply